Skip to main content
Premium Trial:

Request an Annual Quote

Alere to Market VitaPath Genetics' Spina Bifida Assay

NEW YORK (GenomeWeb News) – Alere has licensed the worldwide marketing rights to VitaPath Genetics' spina bifida risk assessment assay, the companies announced Wednesday.

The deal also gives Alere the right to develop with Foster City, Calif.-based VitaPath additional product line extensions mainly focusing on fetal health.

Financial and other terms of the deal were not disclosed.

VitaPath's assay is a genetic test that identifies elevated risk in women of childbearing age for spina bifida, which can be prevented with folic acid. The assay is expected to be launched in 2012.

VitaPath is a developing DNA-based tests. It raised $6 million in a Series A financing round in 2009.

Alere, based in Waltham, Mass., develops and manufactures diagnostics products.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.